Is Grastofil the same as Neupogen?
Neupogen and Grastofil are not interchangeable products. As of the August 2017 formulary update, new prescriptions for filgrastim for ODB eligible patients will be dispensed Grastofil, unless it specifies Neupogen with the appropriate LU code. Prescribers should notify their patients of the switch.
What are the side effects of Grastofil?
The most common side effect with Grastofil (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). Other side effects may be seen in more than 1 patient in 10, depending on the condition that Grastofil is being used for.
What is the difference between pegfilgrastim and filgrastim?
Treatment regimens differ slightly: filgrastim is administered daily for up to a maximum of 14 days, either subcutaneously or intravenously, whereas pegfilgrastim treatment involves a single SC dose per chemotherapy cycle with no restrictions to every 14-day cycles only.
Who owns Neupogen?
Genentech Inc., the biotechnology industry pioneer, has three approved drugs but it is now 60 percent owned by Roche, the huge Swiss pharmaceutical company.
How do you administer Grastofil?
The recommended starting dose of Grastofil® in adult patients is 5 µg/kg/day, administered as a single daily injection by subcutaneous bolus injection, by short intravenous infusion (15 to 30 minutes), or by continuous subcutaneous or continuous intravenous infusion.
Is Grastofil a brand name?
Prescribers should ensure all prescriptions for filgrastim going forward indicate the brand name of the product requested, either Grastofil (filgrastim) or Neupogen (filgrastim).
When should I stop Grastofil?
Stop taking the medication and seek immediate medical attention if any of the following occur: signs of acute respiratory distress syndrome (e.g., fever, shortness of breath, cough, or lung congestion)
When should I take Lapelga?
It must be given at least 24 hours after your course of chemotherapy. There should be a 2-week period between your pegfilgrastim dose and your next chemotherapy. If you miss your pegfilgrastim dose, check with your doctor before taking the missed dose.
Is there an alternative to filgrastim?
For a large healthcare system, the arrival of a cheaper alternative to filgrastim prompted the conversion to using tbo-filgrastim as the preferrred granulocyte-colony stimulating factor. The results were shared in a study published by the Journal of Managed Care & Specialty Pharmacy.
What is the other name for filgrastim?
Neupogen, Granix and Zarxio are trade names for filgrastim. Granulocyte – colony stimulating factor (G-CSF) is another name for filgrastim. In some cases, health care professionals may use the trade name Neupogen, Granix or Zarxio when referring to the generic drug name filgrastim.
When was Neupogen approved?
On March 30, 2015, FDA approved use of Neupogen (filgrastim) to treat adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS).
What is the drug Zarxio used for?
ZARXIO is used to reduce the risk of infection in patients with some tumors who are receiving strong chemotherapy that may cause severe neutropenia with fever.
What is Grastofil used to treat?
Grastofil is a medicine that contains the active substance filgrastim. Grastofil is used to stimulate the production of white blood cells in the following situations: to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia…
What are the risks associated with Grastofil?
What are the risks associated with Grastofil? The most common side effects with Grastofil (which may affect more than 1 in 10 people) are fever, musculoskeletal pain (pain in the muscles and bones), anaemia (low red blood cell counts), vomiting and nausea (feeling sick).
How is Grastofil made?
The filgrastim in Grastofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim. What benefits of Grastofil have been shown in studies?
What is the difference between Grastofil (filgrastim) and Neupogen?
Grastofil and Neupogen are both filgrastim products. Filgrastim is a hematopoietic agent medicine that helps to prevent or treat neutropenia (low white blood cell count) during cancer treatment. Grastofil (filgrastim) is approved by Health Canada as a subsequent entry biologic (SEB) to Neupogen.